| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/31/2011 | WO2011017299A3 PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE |
| 03/31/2011 | WO2011016049A3 A stable composition of ready-to-use gemcitabine injection |
| 03/31/2011 | WO2011015892A3 Novel crystal form of cdb - 4124 and proces s for the preparation thereof |
| 03/31/2011 | WO2011015692A3 Use of maslinic acid for treating nociceptive, inflammatory and neurogenic pain |
| 03/31/2011 | WO2011015646A3 Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 03/31/2011 | WO2011012698A3 Phthalocyanine derivative consisting of a mixture of 4 isomers |
| 03/31/2011 | WO2011012659A3 Diethyl 4-(4-fluorobenzylamino)-1,2-phenylenedicarbamate, and salts thereof |
| 03/31/2011 | WO2011009082A3 Compositions comprising human rhbdf1-modulating nucleic acids and methods of use |
| 03/31/2011 | WO2011004195A3 Cyclic triazo sodium channel blockers |
| 03/31/2011 | WO2011003870A3 Mini-pegylated corticosteroids, compositions including same, and methods of making and using same |
| 03/31/2011 | WO2011002808A8 Hcv protease inhibitors and uses thereof |
| 03/31/2011 | WO2010151740A3 Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| 03/31/2011 | WO2010149658A3 Pharmaceutical composition comprising gamma - butyrobetaine and meldonium |
| 03/31/2011 | WO2010144499A3 Urea derivatives as kinase inhibitors |
| 03/31/2011 | WO2010143150A3 Process for stereoselective preparation of an intermediate of protease inhibitors |
| 03/31/2011 | WO2010142663A8 Unsaturated fatty acid monoesters and diesters on ascorbic acid and cosmetic uses thereof |
| 03/31/2011 | WO2010141768A3 Polycyclic antagonists of lysophosphatidic acid receptors |
| 03/31/2011 | WO2010141680A3 Hedgehog pathway antagonists and methods of use |
| 03/31/2011 | WO2010141074A3 O-glcnac transferase inhibitors and uses thereof |
| 03/31/2011 | WO2010135429A3 Compositions for modulating a kinase cascade and mehtods of use thereof |
| 03/31/2011 | WO2010134939A3 Mammalian genes involved in infection |
| 03/31/2011 | WO2010132882A3 Sublingual dexmedetomidine compositions and methods of use thereof |
| 03/31/2011 | WO2010132879A3 Multicomponent degradable cationic polymers |
| 03/31/2011 | WO2010132852A3 Protease inhibitors |
| 03/31/2011 | WO2010132580A3 Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
| 03/31/2011 | WO2010132507A3 Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
| 03/31/2011 | WO2010132390A3 Method of decreasing ubiquitylated protein levels |
| 03/31/2011 | WO2010129636A3 Lenalidomide polymorph |
| 03/31/2011 | WO2010129524A3 Plant medicinal compounds |
| 03/31/2011 | WO2010129313A3 Cosmetic compositions comprising cyanodiphenylacrylates |
| 03/31/2011 | WO2010128807A3 Pharmaceutical composition for preventing or treating neuronal damage and neurological diseases |
| 03/31/2011 | WO2010127197A3 Method and composition for treating diabetic ketoacidosis |
| 03/31/2011 | WO2010124873A8 3- (2, 2, 2, trimethylhydrazinium) propionate dihydrate (meldonium) for treating parkinson' s disease |
| 03/31/2011 | WO2010121177A3 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| 03/31/2011 | WO2010120797A3 Methods of reduction of interpatient variability |
| 03/31/2011 | WO2010119424A3 Composition for regulating the metabolism of lipids |
| 03/31/2011 | WO2010118405A3 Compositions and methods for reducing hangover symptoms |
| 03/31/2011 | WO2010118330A3 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease |
| 03/31/2011 | WO2010118250A3 Methods and compositions of pi-3 kinase inhibitors for treating fibrosis |
| 03/31/2011 | WO2010117974A3 Hiv-resistant stem cells and uses thereof |
| 03/31/2011 | WO2010117829A3 Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome |
| 03/31/2011 | WO2010117639A3 Inhibition of prostglandin e2 receptors for the treatment of endometriosis |
| 03/31/2011 | WO2010117241A3 Composition for prevention or treatment of hypertrophic scars or keloids |
| 03/31/2011 | WO2010116141A3 Drug combination for the treatment of proteostatic diseases |
| 03/31/2011 | WO2010114919A3 Metnase and intnase inhibitors and their use in treating cancer |
| 03/31/2011 | WO2010108187A3 Compounds and methods for treating mammalian gastrointestinal microbial infections |
| 03/31/2011 | WO2010108028A3 Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| 03/31/2011 | WO2010108016A3 Compositions and methods for sparing muscle in renal insufficiency and during hemodialysis |
| 03/31/2011 | WO2010106166A3 Radiolabelled pyridinyl derivatives for in-vivo imaging |
| 03/31/2011 | WO2010104998A3 Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mnce) |
| 03/31/2011 | WO2010104598A3 Kinase protein binding inhibitors |
| 03/31/2011 | WO2010096170A3 Inhibition of trna synthetases and therapeutic applications thereof |
| 03/31/2011 | WO2010093787A3 Aminopyridine dimer compounds, compositions and related methods for neuronal nitric oxide synthase inhibition |
| 03/31/2011 | WO2010089566A3 Composition for treatment of skin |
| 03/31/2011 | WO2010088414A3 Subunit selective nmda receptor potentiators for the treatment of neurological conditions |
| 03/31/2011 | WO2010085749A3 Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability |
| 03/31/2011 | WO2010085377A3 Hydroxamic acid derivatives |
| 03/31/2011 | WO2010083501A3 Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold |
| 03/31/2011 | WO2010083328A3 Methods for screening and compounds that protect against amyloid diseases |
| 03/31/2011 | WO2010066629A3 Novel azaindoles |
| 03/31/2011 | WO2010030995A8 Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
| 03/31/2011 | WO2010019271A8 Fluorescent regulators of rassf1a expression and human cancer cell proliferation |
| 03/31/2011 | WO2010004256A8 Controlled release treatment of depression |
| 03/31/2011 | WO2010001257A3 Novel solid state forms of laquinimod and its sodium salt |
| 03/31/2011 | WO2009129246A3 Compositions and methods for preparing and using same |
| 03/31/2011 | WO2009077858A3 Hemioxalate salt of eletriptan |
| 03/31/2011 | US20110077737 Tunably Crosslinked Polysaccharide Compositions |
| 03/31/2011 | US20110077702 Means and Methods for Influencing Electrical Activity of Cells |
| 03/31/2011 | US20110077682 Hemorrhage Control Devices and Methods |
| 03/31/2011 | US20110077581 Targeted cellular delivery of nanoparticles |
| 03/31/2011 | US20110077402 Administration of dipeptidyl peptidase inhibitors |
| 03/31/2011 | US20110077399 Substituted Azole Derivatives as Therapeutic Agents |
| 03/31/2011 | US20110077307 Astaxanthin-containing pet foods |
| 03/31/2011 | US20110077306 Stat3 inhibiting compositions and methods |
| 03/31/2011 | US20110077305 5-lipoxygenase inhibitors |
| 03/31/2011 | US20110077304 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus. |
| 03/31/2011 | US20110077303 Increasing glutathione levels for therapy |
| 03/31/2011 | US20110077302 Enzymatic synthesis of sphingolipids |
| 03/31/2011 | US20110077301 Novel methods of administering a mixture of fatty acids for the treatment of non-human mammals |
| 03/31/2011 | US20110077300 Metabolic Benefits to Butyrate as a Chronic Diet Supplement |
| 03/31/2011 | US20110077299 Inhibitors of alpha4 mediated cell adhesion |
| 03/31/2011 | US20110077298 Retinoid Derivative and Pharmaceutical Composition and Use Thereof |
| 03/31/2011 | US20110077297 Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
| 03/31/2011 | US20110077296 Method and composition for delivering zinc to the nasal membrane |
| 03/31/2011 | US20110077295 Andrographolide derivatives and use thereof in manufacture of medicaments |
| 03/31/2011 | US20110077294 R-(-) / s-(+)-7-[3-n substituted amino-2 hydroxypropoxy] flavones |
| 03/31/2011 | US20110077293 GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY |
| 03/31/2011 | US20110077291 Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof |
| 03/31/2011 | US20110077290 Heterocyclic compounds and thrombopoietin receptor activators |
| 03/31/2011 | US20110077289 Method of treating pneumoconiosis with oligodeoxynucleotides |
| 03/31/2011 | US20110077288 Pharmaceutical Compositions for Treatment of MicroRNA Related Diseases |
| 03/31/2011 | US20110077287 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions |
| 03/31/2011 | US20110077286 Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof |
| 03/31/2011 | US20110077285 Rna antagonist compounds for the modulation of pik3ca expression |
| 03/31/2011 | US20110077284 Dry powder compositions for rna influenza therapeutics |
| 03/31/2011 | US20110077283 Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
| 03/31/2011 | US20110077282 Novel compounds from antrodia camphorata |
| 03/31/2011 | US20110077281 Formulations Comprising Triptain Compounds |
| 03/31/2011 | US20110077280 Hepatitis C Virus Inhibitors |
| 03/31/2011 | US20110077279 Angiotensin ii receptor antagonists |